Lifastuzumab vedotin | Sodium Channel inhibitor | Read Reviews & Product Use Citations

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

CAS No. 1401812-88-1

Click to purchase products related to Lifastuzumab vedotin

Purity & Quality Control

Batch: D401001 Purity: 99% Protein concentration: 8.79mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective Sodium Channel Inhibitors

Biological Activity

Description	Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

References
[1] Banerjee S, et al. Ann Oncol. 2018;29(4):917-923.

References

[1] Banerjee S, et al. Ann Oncol. 2018;29(4):917-923.

Product Details

CAS No.	1401812-88-1
ADC antiody	Lifastuzumab
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field